The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

BACKGROUND: Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Demuth, Christina, Madsen, Anne Tranberg, Weber, Britta, Wu, Lin, Meldgaard, Peter, Sorensen, Boe Sandahl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815238/
https://www.ncbi.nlm.nih.gov/pubmed/29448920
http://dx.doi.org/10.1186/s12885-018-4108-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815238/
https://www.ncbi.nlm.nih.gov/pubmed/29448920
http://dx.doi.org/10.1186/s12885-018-4108-0

Ejemplares similares